Why the study?
Sudden cardiac death is a significant cause of increased mortality in schizophrenia and schizoaffective disorders, with cardiac arrhythmia being a cause and ECG abnormalities linked to antipsychotic drug use.
Does psychotropic polypharmacy increase the risk of electrocardiographic abnormalities in patients with schizophrenia and schizoaffective disorders?
Does psychotropic polypharmacy increase the risk of electrocardiographic abnormalities in patients with schizophrenia and schizoaffective disorders?
A high prevalence of ECG abnormalities exists in patients with schizophrenia and schizoaffective disorders regardless of psychotropic polypharmacy, highlighting the need for routine ECG screening in this population.
ECG monitoring beyond QTc warranted in long-stay schizophrenia inpatients; leaves open predictive value for SCD and need for intervention trials.
Background: Sudden cardiac death (SCD) is a significant cause for increased mortality in people with schizophrenia and schizoaffective disorders. Cardiac arrhythmia is one cause of SCD. Electrocardiographic (ECG) abnormalities predictive of arrhythmias are associated with antipsychotic drug use. Method: This chart audit examined the types and frequency of ECG abnormalities (ECG-Abs) in 169 patients with schizophrenia and schizoaffective disorder in a long-stay inpatient unit. We examined the association of ECG-Abs with demographic details and psychotropic drug prescription using chi-square test, Fisher’s Exact test, independent two-sample t-test, Pearson’s correlation, and one-way ANOVA. Results: Eighty-eight patients (52.1%) recorded at least one ECG-Ab, and 20.7% had two or more ECG-Abs. The use of multiple antipsychotics, with or without other psychotropic drugs, did not associate significantly with the presence or number of ECG-Abs. Conclusion: A significant proportion of patients with schizophrenia and schizoaffective disorder have ECG-Abs other than prolonged QTc interval, which can predispose them to cardiac arrhythmias. The abnormalities were not limited to patients on psychotropic polypharmacy. ECG evaluation is indicated for all patients and should consider various electrical abnormalities to identify arrhythmia risk.
No takes yet. Share an insight, caveat, or question.
Srinivasan et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: